Officer & Director Emily Leproust Files Intent to Sell $1.6M in Shares
TWST has more than doubled off its 52-week low of $23.3.
Summary
An Officer and Director of Twist Bioscience Corp has filed an intent to sell $1.63 million in company stock, continuing a pattern of executive share sales.
Key Events · Ownership and Investor Activity · TWST
-
Officer & Director Files Intent to Sell
Emily M. Leproust, an Officer and Director, has filed a Form 144 indicating an intent to sell 25,017 shares of common stock, valued at approximately $1,633,407.23.
-
Continuation of Recent Sales Pattern
This proposed sale follows previous sales by Ms. Leproust totaling 50,133 shares for gross proceeds of $3,059,801.27 over the past three months, indicating an ongoing distribution trend by a key executive.
-
Selling Near 52-Week Highs
The intent to sell comes as Twist Bioscience stock is trading near its 52-week high of $66.94, suggesting the executive is capitalizing on the stock's strong performance.
Analysis · TWST · Life Sciences
Emily M. Leproust, an Officer and Director, has filed an intent to sell an additional $1.63 million worth of common stock. This proposed sale follows approximately $3.06 million in sales by Leproust over the past three months, indicating a consistent pattern of distribution by a key executive. The selling activity occurs while the stock is trading near its 52-week high, which could be interpreted as an executive locking in gains, but also represents a reduction in insider ownership during a period of strong stock performance.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 29.6% of the 2932 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TWST was trading at $64.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $23.30 to $66.94. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.